Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Nanomaterials (Basel, Switzerland)
|
July 9, 2020
Periodic Microstructures Fabricated by Laser Interference with Subsequent Etching
Shuang-Ning Yang, Xue-Qing Liu, Jia-Xin Zheng, et al.
Asian Pacific Journal of Cancer Prevention : APJCP
|
October 6, 2015
Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy
Yu-Lei Gu, Chao Lan, Hui Pei, et al.
Optics Letters
|
May 16, 2019
Ultra-smooth micro-optical components of various geometries
Xue-Qing Liu, Shuang-Ning Yang, Yun-Lu Sun, et al.
Signal Transduction and Targeted Therapy
|
April 2, 2024
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial
Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Nanomaterials (Basel, Switzerland)
|
July 9, 2020
Periodic Microstructures Fabricated by Laser Interference with Subsequent Etching
Shuang-Ning Yang, Xue-Qing Liu, Jia-Xin Zheng, et al.
Asian Pacific Journal of Cancer Prevention : APJCP
|
October 6, 2015
Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy
Yu-Lei Gu, Chao Lan, Hui Pei, et al.
Optics Letters
|
May 16, 2019
Ultra-smooth micro-optical components of various geometries
Xue-Qing Liu, Shuang-Ning Yang, Yun-Lu Sun, et al.
Signal Transduction and Targeted Therapy
|
April 2, 2024
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial
Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, et al.
Page
of 1